STTR Phase I: Steroid-eluting thread for the treatment of rhinitis

这一小型企业技术转移(STTR)第一阶段项目的更广泛的影响/商业潜力是一种减少并发症和改善鼻炎患者预后的新型微创手术选择。将开发一种可生物吸收的类固醇洗脱缝合和外科植入程序，以在耳鼻咽喉科医生或耳鼻喉专家的护理下改善600万名鼻炎患者的预后。拟议的缝合系统和外科套装植入程序实现了一种临时治疗，通过一次办公室访问就可以取代目前对慢性、每日、局部喷洒和/或长期免疫治疗的需要。可生物吸收的药物洗脱平台还为洗脱包括抗生素和抗真菌疗法在内的其他药物提供了潜在的可扩展性。这个小型企业技术转移第一阶段项目旨在提供一种原型类固醇洗脱可溶线和一种引入的手术工具。该项目由几个步骤组成，包括可溶解聚合物的配方和使用热熔融挤压(HME)的原型。这一努力将推动鼻腔用优化药物洗脱线的平台设计和开发。该系统将使用首选的呋喃莫米松类固醇进行设计，并在临床前动物模型中表征药物洗脱特性。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this this Small Business Technology Transfer (STTR) Phase I project is a novel, minimally invasive, surgical option for reducing complications and improving outcomes for rhinitis patients. A bioabsorbable, steroid-eluting suture and surgical implant procedure will be developed to improve outcomes for 6 million patients suffering from rhinitis under the care of otolaryngologists, or ear, nose and throat specialists. The proposed suture system and surgical suite implant procedure enables a temporary therapy that replaces the need for current chronic, daily, topical sprays and/or long-term immunotherapy with a single in-office visit. The bioabsorbable, drug-eluting platform also provides potential extensibility for eluting other medications including antibiotic and antifungal therapies. This Small Business Technology Transfer Phase I project aims to deliver a prototype steroid-eluting dissolvable thread with an introducing surgical tool. The project is comprised of several steps including the formulation of dissolvable polymers, and prototyping using Hot Melt Extrusion (HME). This effort will advance the platform design and development of optimized drug-elution thread for use in the nasal cavity. The system will be designed using the preferred steroid of mometasone furoate and characterized for drug elution properties in a preclinical animal model.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.